CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sio Gene Therapies Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sio Gene Therapies Inc
1501 Broadway, 12Th Floor
Phone: (302) 636-5400p:302 636-5400 NEW YORK, NY  10036  United States Fax: (302) 636-5454f:302 636-5454
This company ceased filing statements with the SEC on 4/25/2023.
On 2/7/2024, Sio Gene Therapies, Inc's Board of Directors and Stockholders approved the Liquidation of the Company under a Plan of Complete Liquidation and Dissolution. The Certificate of Dissolution filed with the Secretary of State of the State of Delaware provides for the dissolution of Sio Gene Therapies Inc under the General Corporation Law of the State of Delaware.
This company is no longer actively traded on any major stock exchange.
Business Summary
Sio Gene Therapies Inc. was a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The Company has not generated any revenue.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20223/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Frank M.Torti 44 9/1/2018 9/1/2018
Chief Executive Officer, Director PavanCheruvu 39 11/1/2020 9/1/2018
Chief Financial Officer, Chief Accounting Officer, General Counsel David W.Nassif 67 11/1/2020 11/1/2020
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Axovant Sciences Inc. 11 Times Square New York NY United States

Business Names
Business Name
Axovant Holdings Limited
Axovant Sciences GmbH
Sio Europe Limited

General Information
Number of Employees: 12 (As of 6/3/2022)
Outstanding Shares: 73,975,196 (As of 2/14/2023)
Shareholders: 3
Stock Exchange: OTC
Federal Tax Id: 981333697
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024